Skip to main content
Fig. 7 | Journal of Nanobiotechnology

Fig. 7

From: CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

Fig. 7

si-circNUP50 and platinum co-delivery using nanosystems to overcome platinum resistance in an OC tumour model. A Structure of the Psc@DPP co-delivery nanosystem. B and C The particle size of Psc@DPP is 150 nm, and the zeta potential of Psc@DPP is + 15 mV. D The transmission electron microscopy image of Psc@DPP. E Fluorescence signals corresponding to platinumCy3 and si-circNUP50Cy5 on Psc@DPP were statistically analysed using Pearson’s correlation test. F The Pearson’s correlation coefficient of platinumCy3 and si-circNUP50Cy5 on Psc@DPP was 0.86. G After co-incubating Psc@DPP with ovarian tumour cells for 4 h, Psc@DPPs delivered platinumCy3 and si-circNUP50Cy5 into OC cells. H The serum stability of Psc@DPP within 24 h and the storage stability of the nanoparticles within 7 days was good. I and J The fluorescence intensity was significantly lower in the Psc@DPP group compared than in the PBS and platinum groups, whereas there was no significant change in fluorescence intensity in the platinum + si-circNUP50 group. K Haematoxylin and eosin staining of OC tissues revealed decreased tumour area in the Psc@DPP group when compared with that in the other groups

Back to article page